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Background: The role for warfarin combined with dual antiplatelet therapy (DAPT) in nonvalvular atrial fibrillation (AF) patients after percutaneous 
coronary interventions (PCI) is unclear. We conducted a single centre, retrospective study to examine cerebrovascular ischemic events and bleeding 
risk in nonvalvular AF patients post PCI, who were treated with DAPT vs. DAPT+warfarin (triple therapy, TT) to determine the optimal medical regimen.
Methods: Nonvalvular AF patients who underwent PCI from 2000 to 2009 were identified from hospitalization and PCI databases. Patient clinical 
characteristics, CHADS2 score, PCI details, antithrombotic therapy and its duration were recorded. Clinical outcomes were obtained from hospital 
records, death registries and administrative databases. Primary composite endpoint was death, ischemic stroke or transient ischemic attack. 
Secondary endpoints included bleeding and blood transfusion (BT) rates.
Results: There were 602 patients included; 220 given DAPT and 382 TT. Duration of DAPT/TT was 5.9±5.0 months (5.8±5.0 months for TT, 6.1±4.9 
months for DAPT). Baseline patient characteristics were similar except for higher CHADS2 (2.6 vs 2.1), driven by older age (72.9 vs 70.5 years), 
more heart failure (49.2% vs 36.9%) and higher previous stroke rate (14.4% vs 6.4%) in TT group. In view of higher CHADS2 in TT group, we stratified 
cerebrovascular ischaemic events by low (≤2) and high (>2) CHADS2 scores. High CHADS2 was associated with more primary outcomes regardless 
of TT or DAPT therapy (O.R. 1.585, C.I. 1.225 - 2.050). There was no difference in primary outcome with TT vs DAPT use in low or high CHADS2 groups, 
but more gastrointestinal (GI) bleeds occurred with TT use (2.6% vs 0.5%, p<0.05). There were no differences in major bleeding or BT rates between 
groups.
Conclusions: The use of TT compared to DAPT was not associated with reduction in cerebrovascular ischaemic events in nonvalvular AF patients 
post PCI regardless of CHADS2 score. There was a 5-fold increase in GI bleed with TT use. These results suggest exercising caution when using TT in 
nonvalvular AF patients post PCI. DAPT alone may be safer and does not appear to be associated with increased stroke rate.
